BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clinic Proceedings 2020;95:758-69. [DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Taha AE. Raw Animal Meats as Potential Sources of Clostridium difficile in Al-Jouf, Saudi Arabia. Food Sci Anim Resour 2021;41:883-93. [PMID: 34632406 DOI: 10.5851/kosfa.2021.e44] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
3 Cortés P, Bi Y, Stancampiano F, Valery JR, Cooper JH, Harris DM. Clostridioides Difficile Infection: A comprehensive review for primary providers. Rom J Intern Med 2021. [PMID: 33713592 DOI: 10.2478/rjim-2021-0010] [Reference Citation Analysis]
4 Smith-Peter E, Séguin DL, St-Pierre É, Sekulovic O, Jeanneau S, Tremblay-Tétreault C, Lamontagne AM, Jacques PÉ, Lafontaine DA, Fortier LC. Inactivation of the riboswitch-controlled GMP synthase GuaA in Clostridioides difficile is associated with severe growth defects and poor infectivity in a mouse model of infection. RNA Biol 2021;:1-12. [PMID: 34612173 DOI: 10.1080/15476286.2021.1978768] [Reference Citation Analysis]
5 Correa-Martínez CL, Hagemeier NCJ, Froböse NJ, Kampmeier S. Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci. Pharmaceuticals (Basel) 2021;14:1066. [PMID: 34832848 DOI: 10.3390/ph14111066] [Reference Citation Analysis]
6 Khanna S. A defined microbiome therapeutic prevents recurrent Clostridioides difficile. Lancet Gastroenterol Hepatol 2021;6:255-6. [PMID: 33631103 DOI: 10.1016/S2468-1253(21)00011-X] [Reference Citation Analysis]
7 Phothichaisri W, Chankhamhaengdecha S, Janvilisri T, Nuadthaisong J, Phetruen T, Fagan RP, Chanarat S. Potential Role of the Host-Derived Cell-Wall Binding Domain of Endolysin CD16/50L as a Molecular Anchor in Preservation of Uninfected Clostridioides difficile for New Rounds of Phage Infection. Microbiol Spectr 2022;:e0236121. [PMID: 35377223 DOI: 10.1128/spectrum.02361-21] [Reference Citation Analysis]
8 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
9 Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc 2021;96:1418-25. [PMID: 34088413 DOI: 10.1016/j.mayocp.2021.04.005] [Reference Citation Analysis]
10 Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC, Mohammadi I, Teigland C, Amin A. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. Journal of the American Medical Directors Association 2022. [DOI: 10.1016/j.jamda.2022.01.075] [Reference Citation Analysis]
11 Bassotti G, Fruganti A, Maconi G, Marconi P, Fettucciari K. Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network. J Inflamm Res 2021;14:7443-53. [PMID: 35002278 DOI: 10.2147/JIR.S328628] [Reference Citation Analysis]
12 Mahadari MK, Jennepalli S, Tague AJ, Putsathit P, Hutton ML, Hammer KA, Knight DR, Riley TV, Lyras D, Keller PA, Pyne SG. Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model. Antibiotics (Basel) 2021;10:913. [PMID: 34438963 DOI: 10.3390/antibiotics10080913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sbeit W, Kadah A, Shahin A, Abed N, Haddad H, Jabbour A, Said Ahmad H, Pellicano R, Khoury T, Mari A. Predictors of in-hospital mortality among patients with clostridium difficile infection: a multicenter study. Minerva Med 2021;112:124-9. [PMID: 33205642 DOI: 10.23736/S0026-4806.20.07139-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Fehily SR, Basnayake C, Wright EK, Kamm MA. The gut microbiota and gut disease. Intern Med J 2021;51:1594-604. [PMID: 34664371 DOI: 10.1111/imj.15520] [Reference Citation Analysis]
15 Khanna S. Fecal transplant clinical trials for Clostridioides difficile: an interview with Sahil Khanna. Future Microbiol 2020;15:709-12. [PMID: 32677453 DOI: 10.2217/fmb-2020-0102] [Reference Citation Analysis]
16 Pomares Bascuñana RÁ, Veses V, Sheth CC. Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis. Lett Appl Microbiol 2021;73:149-58. [PMID: 33864273 DOI: 10.1111/lam.13486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]